Diverse alterations associated with resistance to KRAS(G12C) inhibition

  • 1.

    Ostrem, J. M., Peters, U., Sos, M. L., Wells, J. A. & Shokat, K. M. K-Ras(G12C) inhibitors allosterically control GTP affinity and effector interactions. Nature 503, 548–551 (2013).

    ADS 
    CAS 
    Article 

    Google Scholar
     

  • 2.

    Lito, P., Solomon, M., Li, L. S., Hansen, R. & Rosen, N. Allele-specific inhibitors inactivate mutant KRAS G12C by a trapping mechanism. Science 351, 604–608 (2016).

    ADS 
    CAS 
    Article 

    Google Scholar
     

  • 3.

    Patricelli, M. P. et al. Selective inhibition of oncogenic KRAS output with small molecules targeting the inactive state. Cancer Discov. 6, 316–329 (2016).

    CAS 
    Article 

    Google Scholar
     

  • 4.

    Janes, M. R. et al. Targeting KRAS mutant cancers with a covalent G12C-specific inhibitor. Cell 172, 578–589.e17 (2018).

    CAS 
    Article 

    Google Scholar
     

  • 5.

    Canon, J. et al. The clinical KRAS(G12C) inhibitor AMG 510 drives anti-tumour immunity. Nature 575, 217–223 (2019).

    ADS 
    CAS 
    Article 

    Google Scholar
     

  • 6.

    Hallin, J. et al. The KRAS(G12C) inhibitor MRTX849 provides insight toward therapeutic susceptibility of KRAS-mutant cancers in mouse models and patients. Cancer Discov. 10, 54–71 (2020).

    CAS 
    Article 

    Google Scholar
     

  • 7.

    Kim, D., Xue, J. Y. & Lito, P. Targeting KRAS(G12C): from inhibitory mechanism to modulation of antitumor effects in patients. Cell 183, 850–859 (2020).

    CAS 
    Article 

    Google Scholar
     

  • 8.

    Xue, J. Y. et al. Rapid non-uniform adaptation to conformation-specific KRAS(G12C) inhibition. Nature 577, 421–425 (2020).

    ADS 
    CAS 
    Article 

    Google Scholar
     

  • 9.

    Hong, D. S. et al. KRAS(G12C) inhibition with sotorasib in advanced solid tumors. N. Engl. J. Med. 383, 1207–1217 (2020).

    CAS 
    Article 

    Google Scholar
     

  • 10.

    Pylayeva-Gupta, Y., Grabocka, E. & Bar-Sagi, D. RAS oncogenes: weaving a tumorigenic web. Nat. Rev. Cancer 11, 761–774 (2011).

    CAS 
    Article 

    Google Scholar
     

  • 11.

    Simanshu, D. K., Nissley, D. V. & McCormick, F. RAS proteins and their regulators in human disease. Cell 170, 17–33 (2017).

    CAS 
    Article 

    Google Scholar
     

  • 12.

    Karoulia, Z., Gavathiotis, E. & Poulikakos, P. I. New perspectives for targeting RAF kinase in human cancer. Nat. Rev. Cancer 17, 676–691 (2017).

    CAS 
    Article 

    Google Scholar
     

  • 13.

    Riely, G. J. et al. Frequency and distinctive spectrum of KRAS mutations in never smokers with lung adenocarcinoma. Clin. Cancer Res. 14, 5731–5734 (2008).

    CAS 
    Article 

    Google Scholar
     

  • 14.

    Cancer Genome Atlas Research Network. Comprehensive molecular profiling of lung adenocarcinoma. Nature 511, 543-550 (2014).

    ADS 
    Article 

    Google Scholar
     

  • 15.

    Riely, G. J. et al. 99O_PR KRYSTAL-1: activity and preliminary pharmacodynamic (PD) analysis of adagrasib (MRTX849) in patients (Pts) with advanced non-small cell lung cancer (NSCLC) harboring KRASG12C mutation. J. Thoracic Oncol. 16, S751–S752 (2020).

  • 16.

    Misale, S. et al. KRAS G12C NSCLC models are sensitive to direct targeting of KRAS in combination with PI3K inhibition. Clin. Cancer Res. 25, 796–807 (2019).

    CAS 
    Article 

    Google Scholar
     

  • 17.

    Boned Del Rio, I. et al. SHOC2 complex-driven RAF dimerization selectively contributes to ERK pathway dynamics. Proc. Natl Acad. Sci. USA 116, 13330–13339 (2019).

    Article 

    Google Scholar
     

  • 18.

    Jones, G. G. et al. SHOC2 phosphatase-dependent RAF dimerization mediates resistance to MEK inhibition in RAS-mutant cancers. Nat. Commun. 10, 2532 (2019).

    ADS 
    Article 

    Google Scholar
     

  • 19.

    Wohlhieter, C. A. et al. Concurrent mutations in STK11 and KEAP1 promote ferroptosis protection and SCD1 dependence in lung cancer. Cell Rep. 33, 108444 (2020).

    CAS 
    Article 

    Google Scholar
     

  • 20.

    Gao, Y. et al. V211D mutation in MEK1 causes resistance to MEK inhibitors in colon cancer. Cancer Discov. 9, 1182–1191 (2019).

    CAS 
    Article 

    Google Scholar
     

  • 21.

    Miles, L. A. et al. Single-cell mutation analysis of clonal evolution in myeloid malignancies. Nature 587, 477–482 (2020).

    ADS 
    CAS 
    Article 

    Google Scholar
     

  • 22.

    Pellegrino, M. et al. High-throughput single-cell DNA sequencing of acute myeloid leukemia tumors with droplet microfluidics. Genome Res. 28, 1345–1352 (2018).

    CAS 
    Article 

    Google Scholar
     

  • 23.

    Bolger, A. M., Lohse, M. & Usadel, B. Trimmomatic: a flexible trimmer for Illumina sequence data. Bioinformatics 30, 2114–2120 (2014).

    CAS 
    Article 

    Google Scholar
     

  • 24.

    Langmead, B., Trapnell, C., Pop, M. & Salzberg, S. L. Ultrafast and memory-efficient alignment of short DNA sequences to the human genome. Genome Biol. 10, R25 (2009).

    Article 

    Google Scholar
     

  • 25.

    Kim, D. et al. TopHat2: accurate alignment of transcriptomes in the presence of insertions, deletions and gene fusions. Genome Biol. 14, R36 (2013).

    Article 

    Google Scholar
     

  • 26.

    Li, H. et al. The Sequence Alignment/Map format and SAMtools. Bioinformatics 25, 2078–2079 (2009).

    Article 

    Google Scholar
     

  • 27.

    McKenna, A. et al. The Genome Analysis Toolkit: a MapReduce framework for analyzing next-generation DNA sequencing data. Genome Res. 20, 1297–1303 (2010).

    CAS 
    Article 

    Google Scholar
     

  • 28.

    Cheng, D. T. et al. Memorial Sloan Kettering-Integrated Mutation Profiling of Actionable Cancer Targets (MSK-IMPACT): a hybridization capture-based next-generation sequencing clinical assay for solid tumor molecular oncology. J. Mol. Diagn. 17, 251–264 (2015).

    CAS 
    Article 

    Google Scholar
     

  • 29.

    Zehir, A. et al. Mutational landscape of metastatic cancer revealed from prospective clinical sequencing of 10,000 patients. Nat. Med. 23, 703–713 (2017).

    CAS 
    Article 

    Google Scholar
     

  • 30.

    Xue, Y. et al. An approach to suppress the evolution of resistance in BRAF(V600E)-mutant cancer. Nat. Med. 23, 929–937 (2017).

    CAS 
    Article 

    Google Scholar
     

  • Read more here: Source link